Monoclonal Antibodies for Cancer Therapy-Abstract

Monoclonal Antibodies for Cancer Therapy-Abstract - CCKK...

Info iconThis preview shows pages 1–2. Sign up to view the full content.

View Full Document Right Arrow Icon
CCKK D RUG D ELIVERY T ECHNOLOGIES : M ONOCLONAL A NTIBODIES FOR D ELIVERY OF C HEMOTHERAPY D RUGS FOR C ANCER T HERAPY Abstract April 29, 2005 Submitted to Dr. Miguel Bagajewicz Submitted by: Sarah Clawson Paul Cole Sarah Katen Nell Keith
Background image of page 1

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
2 1. Abstract Malignant Gliomas affect six to nine thousand Americans every year: the average sur- vival time for a patient with this disease is 40 to 60 weeks. CCKK Drug Delivery Tech- nologies has developed a treatment utilizing monoclonal antibodies (MAbs) to selectively deliver a chemotherapy drug directly to the tumor cells. The MAb used, 81C6, targets tenascin, which is in the extracellular matrix of the tumor. The antibody will be attached to a micelle and the toxin will be encapsulated within the micelle. This method will in- crease the damage to the tumor cells while decreasing the damage to the rest of the body. CCKK Drug Delivery Technologies will be a drug delivery technology company that will solicit other, larger drug companies to partner in the use of their drug with our immu-
Background image of page 2
This is the end of the preview. Sign up to access the rest of the document.

This note was uploaded on 08/31/2011 for the course CHE 4273 taught by Professor Staff during the Spring '10 term at Oklahoma State.

Page1 / 2

Monoclonal Antibodies for Cancer Therapy-Abstract - CCKK...

This preview shows document pages 1 - 2. Sign up to view the full document.

View Full Document Right Arrow Icon
Ask a homework question - tutors are online